Post-Enhertu Treatment Options for HER2-Positive Metastatic Breast Cancer
After progression on trastuzumab deruxtecan (Enhertu), continue with sequential HER2-targeted therapy, specifically trastuzumab emtansine (T-DM1) or tucatinib-based combinations, as these demonstrate clinical benefit and are feasible in the post-T-DXd setting.
Treatment Algorithm After Enhertu Progression
Primary Recommendation: Continue HER2-Targeted Therapy
The ASCO guidelines explicitly state that if HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy, clinicians should recommend second-line HER2-targeted therapy-based treatment 1. While these guidelines position T-DXd as the preferred second-line agent, the principle of continuing HER2-directed therapy remains valid after T-DXd failure.
Specific Treatment Options
Third-Line Setting (Post-T-DXd):
Tucatinib + Capecitabine + Trastuzumab: This is the preferred strategy in the third-line setting, particularly for patients with or without CNS metastases, given demonstrated survival benefits 2
Trastuzumab Emtansine (T-DM1): If not previously used, T-DM1 remains an option 3
Fourth-Line and Beyond:
- Margetuximab + chemotherapy
- Neratinib + capecitabine
- Trastuzumab + chemotherapy 2
Real-World Evidence Supporting Sequential HER2 Therapy
The EN-SEMBLE study provides critical real-world data on post-T-DXd treatment 4. In 664 patients who received treatment after T-DXd:
- 486/664 patients (73%) received another anti-HER2 therapy as first post-T-DXd treatment
- 361/664 patients received anti-HER2 antibodies
- 113/664 patients received HER2-tyrosine kinase inhibitors (TKIs)
- Median progression-free survival was 4.1 months (95% CI 3.9-4.5)
- Median overall survival was 16.2 months (95% CI 13.8-17.2)
Key finding: Outcomes were similar between anti-HER2 antibodies and HER2-TKIs, indicating both are viable options 4.
Special Considerations
Patients Who Discontinued T-DXd Due to Adverse Events
Real-world data shows that patients who discontinued T-DXd due to adverse events (including ILD) had numerically longer progression-free survival and overall survival with subsequent therapy 4. This suggests these patients may derive particular benefit from continued HER2-targeted treatment.
Patients Who Responded to T-DXd
Those who achieved complete or partial response to T-DXd also demonstrated numerically longer outcomes with subsequent therapy 4, supporting the continuation of HER2-targeted approaches.
Interstitial Lung Disease (ILD) Concerns
Critical safety data: The ILD recurrence/exacerbation rate was only 3.2% during first post-T-DXd treatment 4. This low rate indicates that patients who developed ILD during T-DXd can safely receive subsequent therapies, including other HER2-targeted agents.
HER2 Status Re-evaluation
Important caveat: HER2 loss occurs in 32.4% of patients following T-DXd treatment, with an additional 29.4% showing decreased HER2 expression 5. Re-biopsy and HER2 reassessment should be strongly considered before initiating alternate HER2-targeted therapies that require HER2 overexpression for efficacy 5.
The FDA label for Enhertu specifically recommends reassessing HER2 status if feasible after prior trastuzumab-based therapy 6.
Hormone Receptor-Positive Disease
For patients with HR-positive/HER2-positive disease, the ASCO guidelines allow flexibility 1:
- HER2-targeted therapy plus chemotherapy (preferred)
- Endocrine therapy plus trastuzumab or lapatinib (selected cases)
- Endocrine therapy alone (highly selected cases with low disease burden or contraindications)
When chemotherapy ends, add endocrine therapy to the HER2-targeted therapy when the cancer progresses 1.
CNS Metastases
If CNS involvement is present, tucatinib + capecitabine + trastuzumab should be prioritized over other options given its demonstrated CNS activity 2.
Common Pitfalls to Avoid
Don't abandon HER2-targeted therapy: The evidence strongly supports sequential HER2-directed treatment even after T-DXd progression 4
Don't assume ILD precludes further treatment: The recurrence rate is low (3.2%), and many patients can safely continue with other regimens 4
Don't skip HER2 re-testing: Nearly one-third of patients lose HER2 expression post-T-DXd, which may impact treatment selection 5
Don't use chemotherapy alone: Unless HER2 status has been lost, continue HER2-targeted agents with chemotherapy 1